6月17日 - ** H.C. Wainwright给予药物开发商Galectin Therapeutics GALT.O"买入 "评级；将目标价定为6美元，较上一交易日收盘价上涨233.3%。
** 经纪公司称，Galectin目前正在开发贝拉肽，用于治疗被称为代谢功能障碍相关性脂肪性肝炎（metabolic dysfunction-associated steatohepatitis(MASH)）的慢性肝病，这种疾病可发展为肝硬化、肝衰竭和肝癌。
** H.C. Wainwright 称，GALT 的贝拉果胶是唯一一种正在开发的治疗 MASH 肝硬化的疗法。
** 券商称："初步临床试验显示出令人信服的预防和阻止疾病症状和体征的趋势
** 包括本交易日的走势在内，该股今年累计上涨约 45
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.